Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Tixagevimab/cilgavimab  COVID-19 treatment studies for Tixagev../c..  C19 studies: Tixagev../c..  Tixagev../c..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -368% Improvement Relative Risk Hospitalization 33% Viral clearance -24% c19early.org/tc Lombardi et al. Tixagevimab/c.. for COVID-19 EARLY Is early treatment with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 108 patients in Italy (August - October 2022) Study compares with other mAbs, results vs. placebo may differ Higher mortality (p=0.32) and worse viral clearance (p=0.3), not stat. sig. Lombardi et al., MDPI AG, doi:10.20944/preprints202301.0359.v1 Favors tixagevimab/ci.. Favors other mAbs
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment With Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
Lombardi et al., MDPI AG, doi:10.20944/preprints202301.0359.v1 (Preprint)
Lombardi et al., Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment With Tixagevimab/Cilgavimab.., MDPI AG, doi:10.20944/preprints202301.0359.v1 (Preprint)
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective immunocompromised patients, showing no significant difference between tixagevimab/cilgavimab and other mAbs.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, and BQ.1.1 [Planas]. This study is excluded in the after exclusion results of meta analysis: study compares against another treatment showing significant efficacy.
risk of death, 368.4% higher, RR 4.68, p = 0.32, treatment 1 of 19 (5.3%), control 1 of 89 (1.1%), day 14.
risk of hospitalization, 33.1% lower, RR 0.67, p = 1.00, treatment 1 of 19 (5.3%), control 7 of 89 (7.9%), NNT 38, day 14.
risk of no viral clearance, 23.7% higher, RR 1.24, p = 0.30, treatment 14 of 19 (73.7%), control 53 of 89 (59.6%), day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lombardi et al., 19 Jan 2023, retrospective, Italy, preprint, 21 authors, study period 28 August, 2022 - 15 October, 2022, this trial compares with another treatment - results may be better when compared to placebo.
Contact: andrea.lombardi@unimi.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperTixagev../c..All
Abstract: Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 January 2023 doi:10.20944/preprints202301.0359.v1 Disclaimer/Publisher’s Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content. Preliminary evidence of good safety profile and outcomes of early treatment with tixagevimab/cilgavimab compared to previously employed monoclonal antibodies for COVID19 in immunocompromised patients Andrea Lombardi1,2,3*, Giulia Viero1*, Simone Villa2, Simona Biscarini1, Emanuele Palomba1, Cecilia Azzarà1, Nathalie Iannotti1, Bianca Mariani1, Camilla Genovese1, Mara Tomasello1, Anna Tonizzo1, Marco Fava1, Antonia Grazia Valzano4, Letizia Corinna Morlacchi5, Francesca Donato6, Giuseppe Castellano7, Ramona Cassin8, Maria Carrabba9, Antonio Muscatello1, Andrea Gori1,2,3, Alessandra Bandera1,2,3 1. Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 2. Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, 20122 Milano, Italy 3. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy 4. Clinical Laboratory, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 5. Respiratory Unit and Cystic Fibrosis Adult Center, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 6. A.M. & A. Migliavacca Center for Liver Disease, Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 7. Department of Nephrology, Dialysis, and Renal Transplantation, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 8. Hematology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 9. Department of Internal Medicine, Adult Primary Immunodeficiencies Centre, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy * Shared first authorship Corresponding author: Andrea Lombardi, MD. Department of Pathophysiology and Transplantation, University of Milan, via Francesco Sforza 35, Milan, Italy. 0039-0255034767 andrea.lombardi@unimi.it 1 © 2023 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 January 2023 doi:10.20944/preprints202301.0359.v1 Abstract electronic word count: 242 Main text electronic word count: 1,207 References: 11 Figures and tables: 3 Keywords: monoclonal antibodies; tixagevimab/cilgavimab; immunocompromised 2 Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 January 2023 doi:10.20944/preprints202301.0359.v1 Abstract Objectives Monoclonal antibodies (mAbs) have proven to be a valuable tool against COVID-19, mostly among subjects with risk factors for progression to severe illness. Tixagevimab/cilgavimab (TIX/CIL), a combination of two Fc-modified human monoclonal antibodies, has been recently approved to be employed as early treatment. Methods Two groups of immunocompromised patients exposed to different early treatments (i.e., TIX/CIL vs. other mAbs [casirivimab/imdevimab, bamlanivimab/etesevimab, sotrovimab]) were compared in terms of clinical outcomes (hospitalization and mortality within 14 days..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit